Diethylfumaric acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Diethylfumaric acid
• 英文别名: (E)-2,3-diethylbut-2-enedioic acid
• 化学式: C₈H₁₂O₄
• 分子量: 172.18
• InChiKey: HAHASQAKYSVXBE-AATRIKPKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] COMPOSITION FOR OXIDATION OF ORGANIC SUBSTRATES<br/>[FR] COMPOSITION POUR L'OXYDATION DE SUBSTRATS ORGANIQUES
  申请人：DSM IP ASSETS BV

  公开号：WO2011104333A1

  公开（公告）日：2011-09-01

  The invention relates to a composition comprising a soluble source of manganese, a ligand, a base, hydrogen peroxide and a ketone or an aldehyde, wherein the ligand is a pyridine heterocycle containing carboxylic acid or a precursor thereof, wherein the nitrogen atom of the pyridine ring is capable of coordinating to the carboxylate bonded manganese center, wherein the 2-position relative to the nitrogen atom is part of the N(pyridine)-Mn-O(carboxylate) containing chelate ring and the second 2-position relative to the nitrogen atom in the ring is not a carboxylic acid group. Furthermore, the invention relates to a process for oxidation of an organic substrate using the composition of the invention.

  该发明涉及一种组合物，包括可溶性锰源、配体、碱、过氧化氢和酮或醛，其中配体是含有羧酸或其前体的吡啶杂环，吡啶环的氮原子能够配位到羧酸盐键合的锰中心，相对于氮原子的2位是N（吡啶）-Mn-O（羧酸盐）螯合环的一部分，环中第二个相对于氮原子的2位不是羧酸基团。此外，该发明涉及使用该组合物氧化有机底物的方法。
• COPOLYMERS AND COMPOSITIONS WITH ANTI-ADHESIVE AND ANTIMICROBIAL PROPERTIES
  申请人：BASF SE

  公开号：US20160235062A1

  公开（公告）日：2016-08-18

  The invention relates to a copolymer exhibiting both antimicrobial and anti-adhesive properties as well as to a hydrogel. Said hydrogel is obtained from the inventive copolymer and a substrate. Another part of the invention is a process for making the hydrogel, as well as different uses of the inventive copolymer as well as of the hydrogel.

  该发明涉及一种既具有抗菌和抗粘附性能的共聚物，又涉及一种水凝胶。所述水凝胶是由该创新共聚物和基质制得的。该发明的另一部分是制备水凝胶的方法，以及该创新共聚物和水凝胶的不同用途。
• Method for preparing free base compositions and formulations thereof
  申请人：Xie Jianbo

  公开号：US20070232697A1

  公开（公告）日：2007-10-04

  Disclosed is a process for preparing a free base composition of a pharmaceutical compound comprising combining an acid addition salt of a pharmaceutical compound, at least one solvent and a sufficient amount of at least one base to convert the acid addition salt of the pharmaceutical to a free base of the pharmaceutical, to form a free base composition of the pharmaceutical compound.

  公开了一种制备药物化合物的游离碱组合物的过程，包括将药物化合物的酸盐、至少一种溶剂和足够量的至少一种碱结合在一起，以将药物的酸盐转化为药物的游离碱，形成药物化合物的游离碱组合物。
• [EN] SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF<br/>[FR] SELS D'OUVREURS DES CANAUX POTASSIQUES ATP ET LEURS UTILISATIONS
  申请人：ESSENTIALIS INC

  公开号：WO2013130411A1

  公开（公告）日：2013-09-06

  Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.

  提供了对某些KATP通道开放剂的盐（如重组胰岛素）进行立即或长期管理，以实现治疗涉及KATP通道的疾病或状况的新型药理学、药代动力学、治疗、生理、代谢和成分结果。还提供了制药配方、盐的管理和剂量方法，以实现这些结果并降低治疗个体的不良反应发生率。此外，还提供了联合使用这些盐与其他药物治疗人类和动物疾病的方法。
• Pharmaceutical formulations of potassium ATP channel openers and uses thereof
  申请人：Cowen Madison Neil

  公开号：US20060051418A1

  公开（公告）日：2006-03-09

  Provided are immediate or prolonged administration of certain potassium ATP (K ATP ) channel openers to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving K ATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of K ATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering K ATP channel openers with other drugs to treat diseases of humans and animals.

  本发明提供了立即或长期给予某些钾ATP（KATP）通道开放剂给受试者，以实现治疗涉及KATP通道的疾病或病症的新型药效学、药代动力学、治疗、生理、代谢和组成成果。还提供了制药配方、给药方法和剂量，以实现这些成果并减少治疗个体中不良反应的发生率。此外，还提供了联合给予KATP通道开放剂与其他药物治疗人类和动物疾病的方法。